| Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ... Journal of Clinical Oncology 28 (30), 4594-4600, 2010 | 770 | 2010 |
| Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study JFR Robertson, A Llombart-Cussac, J Rolski, D Feltl, J Dewar, ... Journal of Clinical Oncology 27 (27), 4530-4535, 2009 | 383 | 2009 |
| FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor … J Bergh, PE Jönsson, EK Lidbrink, M Trudeau, W Eiermann, D Brattström, ... Journal of Clinical Oncology 30 (16), 1919-1925, 2012 | 358 | 2012 |
| AKT inhibition in solid tumors with AKT1 mutations DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ... Journal of Clinical Oncology 35 (20), 2251, 2017 | 284 | 2017 |
| Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’study JFR Robertson, JPO Lindemann, A Llombart-Cussac, J Rolski, D Feltl, ... Breast cancer research and treatment 136, 503-511, 2012 | 240 | 2012 |
| A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ... Clinical Cancer Research 24 (9), 2050-2059, 2018 | 114 | 2018 |
| Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) KI Pritchard, J Rolski, Z Papai, L Mauriac, F Cardoso, J Chang, L Panasci, ... Breast cancer research and treatment 123, 453-461, 2010 | 106 | 2010 |
| A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer EP Hamilton, MR Patel, AC Armstrong, RD Baird, K Jhaveri, M Hoch, ... Clinical Cancer Research 24 (15), 3510-3518, 2018 | 97 | 2018 |
| Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers TA Yap, R Kristeleit, V Michalarea, SJ Pettitt, JSJ Lim, S Carreira, D Roda, ... Cancer discovery 10 (10), 1528-1543, 2020 | 86 | 2020 |
| Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic … GR Bernard, B Francois, JP Mira, JL Vincent, RP Dellinger, JA Russell, ... Critical care medicine 42 (3), 504-511, 2014 | 83 | 2014 |
| Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer LM Smyth, K Tamura, M Oliveira, EM Ciruelos, IA Mayer, MP Sablin, ... Clinical Cancer Research 26 (15), 3947-3957, 2020 | 73 | 2020 |
| A good drug made better: the fulvestrant dose-response story JFR Robertson, J Lindemann, S Garnett, E Anderson, RI Nicholson, ... Clinical breast cancer 14 (6), 381-389, 2014 | 73 | 2014 |
| Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors BR Davies, N Guan, A Logie, C Crafter, L Hanson, V Jacobs, N James, ... Molecular cancer therapeutics 14 (11), 2441-2451, 2015 | 72 | 2015 |
| BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with … NC Turner, E Alarcón, AC Armstrong, M Philco, YAL Chuken, MP Sablin, ... Annals of Oncology 30 (5), 774-780, 2019 | 71 | 2019 |
| Durable control of metastatic AKT1-mutant WHO grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363 M Weller, P Roth, F Sahm, I Burghardt, B Schuknecht, EJ Rushing, L Regli, ... Journal of the National Cancer Institute 109 (3), djw320, 2017 | 68 | 2017 |
| Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors K Tamura, J Hashimoto, Y Tanabe, M Kodaira, K Yonemori, T Seto, ... Cancer chemotherapy and pharmacology 77, 787-795, 2016 | 56 | 2016 |
| Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD phase I trial C Paoletti, G Schiavon, EM Dolce, EP Darga, TH Carr, J Geradts, M Hoch, ... Clinical Cancer Research 24 (23), 5860-5872, 2018 | 54 | 2018 |
| Abstract S1-3: A Comparison of Fulvestrant 500 mg with Anastrozole as First-Line Treatment for Advanced Breast Cancer: Follow-Up Analysis from the ‘FIRST’ Study JFR Robertson, JPO Lindemann, A Llombart-Cussac, J Rolski, D Feltl, ... Cancer Research 70 (24_Supplement), S1-3-S1-3, 2010 | 47 | 2010 |
| First Results from FACT–An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in … J Bergh, P Jonsson, E Lidbrink, M Trudeau, W Eiermann, D Brattstrom, ... Cancer Research 69 (24_Supplement), 23-23, 2009 | 38 | 2009 |
| A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer. EP Hamilton, M Oliveira, U Banerji, C Hernando, J Garcia-Corbacho, ... American Society of Clinical Oncology (ASCO), 2020 | 36 | 2020 |
